Appili Therapeutics (APLIF) Stock Price, News & Analysis

Company Overview

Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin in Phase III clinical trials for the treatment of cutaneous leishmaniasis and disfiguring skin infections; and ATI-1701, which is a live-attenuated vaccine in preclinical trials for Francisella tularensis. The company was incorporated in 2015 and is headquartered in Halifax, Canada.

Key Stats

• Today's Range: $0.02 to $0.02
• 50-Day Range: $0.02 to $0.03
• 52-Week Range: $0.01 to $0.04
• Volume: 240,000 shs
• Average Volume: 85,769 shs
• Market Capitalization: $3.01 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Appili Therapeutics Stock Analysis - MarketRank™

Appili Therapeutics scored higher than 19% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Appili Therapeutics.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Appili Therapeutics is -1.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Appili Therapeutics is -1.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.09% of the float of Appili Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Appili Therapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Appili Therapeutics has recently decreased by 17.24%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Appili Therapeutics does not currently pay a dividend.

Dividend Growth

Appili Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.09% of the float of Appili Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Appili Therapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Appili Therapeutics has recently decreased by 17.24%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: N/A

News Sentiment

Appili Therapeutics has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Appili Therapeutics this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Appili Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

11.84% of the stock of Appili Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

APLIF Stock Analysis - Frequently Asked Questions

How have APLIF shares performed this year?

Appili Therapeutics' stock was trading at $0.0280 at the beginning of 2025. Since then, APLIF stock has decreased by 11.4% and is now trading at $0.0248.
View the best growth stocks for 2025 here.

How were Appili Therapeutics' earnings last quarter?

Appili Therapeutics Inc. (OTCMKTS:APLIF) issued its quarterly earnings data on Tuesday, August, 13th. The company reported ($0.01) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.01).

How do I buy shares of Appili Therapeutics?

Shares of APLIF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 8/13/2024
• Today: 4/19/2025
• Fiscal Year End: 3/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:APLIF
• CIK: N/A
• Web: www.appilitherapeutics.com
• Phone: 902-442-4655
• Fax: N/A
• Employees: 8
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.02)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-2,800,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -209.09%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.11
• Quick Ratio: 0.11

Sales & Book Value

• Annual Sales: $630,000.00
• Price / Sales: 4.77
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.05) per share
• Price / Book: -0.50

Miscellaneous

• Outstanding Shares: 121,266,000
• Free Float: 106,908,000
• Market Cap: $3.01 million
• Optionable: Not Optionable
• Beta: -0.54